Latest Industry Insights

We recently spoke to Karoly Nikolich, chairman and chief executive officer of Alkahest, a clinical-stage biotechnology company, to learn more about their approach to developing therapeutics for both neurodegenerative and age-related diseases.

Lab equipment purchases, both big and small, require plenty of thought and can have a big impact on the quality of your science. In this blog, MCI Neuroscience's Adam Tozer highlights some tips to making the best purchases.

NeuroBo Pharmaceuticals’ first lead candidate, NB-01, is positioned as a potential treatment for diabetic neuropathic pain. The candidate, which in 2018 will move into a phase III clinical trial, uses extracts of two species of the plant genus Dioscorea, used in traditional medicine for centuries, but never yet subject to systematic study. We caught up with NeuroBo’s Mark Versavel and Nandan Padukone to find out more.

Dr Jan Dolzer, a scientist-turned-engineer that has spent his career at the leading edge of amplifier development, describes the capability of Sutter's all new digital patch clamp system

With growing pressure on labs to reduce waste and improve sustainability, we spoke to the Sustainability Forum at Agilent to learn more about what the company are doing to help their customers achieve their sustainability goals.

The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners recently announced the launch of Magnolia Neurosciences Corporation – a biopharmaceutical company advancing a new class of neuroprotective medicines.

How do you start, grow and run a successful life science company? To find out we spoke to Dr Yichen Shi, CEO of Axol Bioscience.

Dr. Sven Schönecker from Multi Channel Systems discusses exciting technological developments in the preclinical drug development space for diabetes

We recently spoke to Dr. Hervé Perron, HDR, Chief Scientific Officer at GeNeuro to learn about their progress developing new treatments for neurological and autoimmune diseases associated with pathogenic proteins expressed by human endogenous retroviruses (HERVs).

How do you reliably quantify behavior? Zantiks CEO Dr. Bill Budenberg Explains